The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Merzee is a generic equivalent of Taytulla of Allergan Pharmaceuticals International
Global event to kick off as the post-covid era begins in earnest, with theme "beyond the pandemic, into a next wave"
Ind-Ra maintains a neutral outlook for healthcare in FY23
Aveir VR is specifically designed to be retrieved when therapy needs to evolve or the device needs to be replaced
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
He has done his Masters in Pharmacy (M. Pharm) and Post Graduate Diploma in Personnel Management & Industrial Relations
Subscribe To Our Newsletter & Stay Updated
